Medical imaging software vendor AMICAS Inc. is asking its stockholders to reject an unsolicited proposal from rival Merge Healthcare to buy the company for $6.05 per share.
Boston-based AMICAS in December agreed to sell its business to investment firm Thoma Bravo LLC for $5.35 per share. "This purchase price is fully financed and guaranteed by Thoma Bravo and other first tier private equity funds and is not dependent on unguaranteed, third-party financing," AMICAS said in a Feb. 22 statement.
In contrast, AMICAS calls Milwaukee-based Merge's offer a "highly-conditional proposal" that does not provide sufficient financial guarantees and reasonable protections for stockholders.
In response, Merge Healthcare notes it has received a signed bridge financing commitment from Morgan Stanley to provide $200 million of debt financing. The company also has $40 million of pre-funded equity investments.
More information is available at businesswire.com/news/home/20100222006352/en and
Register or login for access to this item and much more
All Health Data Management content is archived after seven days.
Community members receive:
- All recent and archived articles
- Conference offers and updates
- A full menu of enewsletter options
- Web seminars, white papers, ebooks
Already have an account? Log In
Don't have an account? Register for Free Unlimited Access